Source Articles
Therapeutic Vaccines
Showing 3 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agarwal et al. | 2025 | Prospective | A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma | 10.1158/1078-0432.CCR-24-3403 | NCT03161379 | 18 | 62 | 19.5 | pancreas | primary | Therapeutic Vaccines | Nivolumab, GVAX | — | 18 | extra-cranial | other | primary pancreatic cancer | 33 | 33 | 33 | 5 | 5 | 5 | 6.6 | 6.6 | 6.6 | Treatment-rel. | — | — | 2 | any G3: 4 AEs | any G3: 2 pts |
any G3: ALT increase and AST increase, neutrophil count decrease, white blood cell decrease, anorexia
|
any G3: neutrophil count decrease and WBC decrease, anorexia (thought to be related to SBRT, all in 1 pt)
|
| van 't Land et al. | 2022 | Prospective | Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer | 10.3390/cancers14215299 | NL7578 | 20 | 63 | Missing | pancreas | primary | Therapeutic Vaccines | IM-101 | — | 20 | extra-cranial | other | Pancreas | 40 | 40 | 40 | 5 | 5 | 5 | 8.0 | 8.0 | 8.0 | Treatment-rel. | — | — | 3 | G3: 3 AEs | G3: 3 pts |
G3: GI haemorrhage
|
—
|
| Rodríguez-Ruiz et al. | 2018 | Prospective | Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients | 10.1093/annonc/mdy089 | — | 6 | 54 | Missing | Prostate cancer, Head and neck cancer, other | any | Therapeutic Vaccines | dendritic cell vaccine | dendritic cell vaccines, and hiltonol intratumoral injection | 6 | extra-cranial | lung, liver, LN unspecified, other | peritoneum node, also other sites irradiated but not specified (only specified sites are those that received Hiltonol and SBRT) | 24 | 24 | 24 | 3 | 3 | 3 | 8.0 | 8.0 | 8.0 | Treatment-rel. | — | — | 0 | — | — |
—
|
—
|